Key result
HCV neutralizing monoclonal antibodies exhibit broad neutralization but lower potency than HIV and SARS-CoV-2 antibodies, with HEPC74 uniquely demonstrating both high breadth and potency.
Why the study?
Optimizing HCV vaccine strategies requires inducing both potent and broad neutralizing responses.
HCV neutralizing monoclonal antibodies generally exhibit a trade-off between breadth and potency, highlighting the need for vaccine strategies that can induce both.
Answers are grounded in this paper and cite their sources.
HCV vaccine design should prioritize dual breadth and potency; leaves open whether HEPC74-like responses are elicitable in humans.
• HCV, influenza, and HIV neutralizing monoclonal antibodies (NmAbs) vary in potency. • HCV NmAbs exhibit broad neutralization but have lower potency than HIV and SARS-CoV-2 NmAbs. • A potential trade-off between breadth and potency is observed, particularly in HCV NmAbs. • HEPC74 is the only HCV NmAb demonstrating both high breadth and potency. • Optimizing HCV vaccine strategies requires inducing both potent and broad neutralizing responses.
No takes yet. Share an insight, caveat, or question.
Jamali et al. (2025) conducted a review in HCV. HCV neutralizing monoclonal antibodies (NmAbs) vs. HIV and SARS-CoV-2 NmAbs was evaluated. HCV neutralizing monoclonal antibodies exhibit broad neutralization but lower potency than HIV and SARS-CoV-2 antibodies, with HEPC74 uniquely demonstrating both high breadth and potency.
Synapse has enriched 10 related papers. Consider them for comparative context: